Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Imerys Ch. 11 Trial Abruptly Paused, Celsius Seeks Sanctions No Photo Available

Yun Park

Talc producer Imerys is nearing Chapter 11 plan confirmation after a trial commenced; a plan administrator for Celsius moved to impose... (more story)

Ch. 15 Rulings Boost Possibility Of Purdue Workarounds No Photo Available

Alex Wittenberg

Two recent bankruptcy court decisions that approved nonconsensual third-party releases have spotlighted a growing divide between the r... (more story)

Labor Woes, Fire, Debt Concerns Led Royal Interco To Ch. 11 No Photo Available

Yun Park

Operational setbacks due to labor shortages, a fire at its distribution center last year and reduced supplier credit stemming from con... (more story)